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Gliomas are the most common primary brain tumors in adults.
Only grade I glioma occurring exclusively in children can be
cured by surgery only, while grade II, grade III and grade IV
glioma occurring in adults are diffusely infiltrative diseases
that invariably recur despite the most radical surgery.
Malignant glioma (grade III, anaplastic astrocytoma and grade
IV, glioblastoma, GBM) may arise from a prior lower grade
lesion as a result from sequential accumulation of genetic
aberrations and deregulated signaling pathways (Fig. 1) [1].
Most aggressive gliomas, however will present as a rapidly
growing and debilitating disease de novo. Although indistin-
guishable by histopathology, these tumors will differ on a
molecular level. Better insights into glioma genesis, identifica-
tion of aberrant pathways, mutations and identification of
characteristic molecular defects of certain glioma subtypes have
given rise to expectations that molecularly driven therapy may
also improve outcome of patients suffering from glioma.
Over the last decade targeted therapies have changed the
perspective of many solid tumors. However, despite compel-
ling preclinical data in malignant glioma, controlled clinical
trials have failed to demonstrate an unequivocal benefit from
the addition of novel targeted agents. Primary brain tumors are
highly heterogeneous, and multiple pathways may be dysregu-
lated (Fig. 2) [1] and responsible for glioma development.
Redundancy of signaling pathways demands therapeutic
inhibition of more than only one key pathway to be eventually
successful. Thus pharmacological inhibition with a single
agent may not suffice to demonstrate a clinically measurable
effect. There are additional challenges to be surmounted when
treating malignant glioma. The blood-brain barrier, although
in part disrupted in glioma, may hamper adequate delivery of
many chemotherapeutics or targeted treatment agents to the
brain. Peritumoral edema and increased interstial pressure will
limit passive diffusion. Due to the localization of the disease
in the brain, repeat biopsies with analysis of drug levels in the
tumor and evaluation of the presumed drug target are
inherently difficult. Innovative and presurgical trial designs
are needed, ideally coupled with novel radiological techniques
and biomarker evaluation in the blood and cerebro-spinal
fluid. Finally, pharmacologic interactions (→ enzyme induc-
ing antiepileptics, steroids) may increase drug metabolism and
thus further lower the exposure to many agents.
Overexpression and/or activation of the epidermal growth
factor receptor (EGFR) pathway is present in nearly 50% of
glioblastoma. Small molecule inhibitors specific for the
tyrosine kinase of the EGFR have failed to demonstrate clinical
antitumor activity in recurrent glioma. Strategies are underway
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to combine EGFR-inhibition with inhibitors of downstream
effectors (PI3K/Akt/mTOR). Vaccination strategies targeting
the constitutively activated EGFR variant III (EGFRvIII) are in
clinical trials, unfortunately a pivotal randomized study had to
be discontinuted due to low compliance.
Despite some caveats and disappointing initial clinical
results, targeted antiangiogenic strategies are currently in phase
III clinical trials. The neutralizing anti-vascular endothelial
growth factor (VEGF) monoclonal antibody bevacizumab and
the VEGFR tyrosine kinase inhibitor cediranib (AZD2171)
have shown impressive radiological response rates and a
decrease in the need of corticosteroids in preliminary clinical
trials. Results of a randomized phase III trial for recurrent
glioblastoma of cediranib compared to lomustine (CCNU) and
combination of cediranib and lomustine are expected for the
end of 2010. Bevacizumab is currently being investigated in
two phase III trials in newly diagnosed GBM in addition to
temozolomide and radiotherapy (TMZ/RT).
Inhibition of the tumor-specific integrins αVβ3 and
αVβ5 by cilengitide has shown consistent activity in phase
I and II trials in recurrent glioma. This agent is currently
also undergoing definitive testing in a phase III trial for
newly diagnosed GBM in addition to TMZ/RT.
Conventional radiological evaluation based on contrast
enhancement does not adequately reflect tumor response
and treatment when patients are treated with many of
these novel agents. Considerations for adapted response
criteria have recently been published [2]. Advanced
magnetic resonance imaging (MRI) techniques (perfusion,
permeability, diffusion) and metabolic imaging (positron
emission tomography, MR spectroscopy) add further
diagnostic information and may help assessing treatment
outcome.
A main focus of today’s research is to identify
molecular tumor subclasses by gene signature profiles
allowing for more individualized therapeutic strategies
[3]. The Cancer Genome Atlas Research Network has
recently put forward genomic abnormalities driving tu-
morigenesis in glioblastoma [4]. Correlations between
molecular subtypes, clinical outcome and treatment effi-
cacy are being established [5].
This issue of Targeted Oncology will discuss many of
these aspects in some detail, written by experts in the field.
While enthusiasm at this stage should be tempered, this
illustrates that novel therapies are on the horizon for
patients suffering from a debilitating disease.
Fig. 1 Pathways in the development of malignant gliomas. Olig2
Oligodendrocyte transcription factor 2, VEGF vascular endothelial
growth factor, DCC deleted in colorectal carcinoma, EGFR epidermal
growth factor receptor, LOH loss of heterozygosity, MDM2 murine
double minute 2, PDGF platelet-derived growth factor, PDGFR
platelet-derived growth factor receptor, PI3K phosphatidylinositol 3-
kinase, PTEN phosphatase and tensin homologue, RB retinoblastoma.
Reprinted with permission from Wen PY, Kesari S (2008) Malignant
gliomas in adults. N Engl J Med. 359
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Fig. 2 Major signaling pathways in malignant gliomas and the
corresponding targeted agents in development for glioblastoma. RTK
(receptor tyrosine kinase) inhibitors that target epidermal growth factor
(EGF) receptor include gefitinib, erlotinib, lapatinib, BIBW2992 and
vandetanib; those that target platelet-derived growth factor (PDGF)
receptor include imatinib, dasatinib, and tandutinib; those that target
vascular endothelial growth factor (VEGF) receptor include cediranib,
pazopanib, sorafenib, sunitinib, vatalanib, vandetanib, and XL184. EGF
receptor antibodies include cetuximab and panitumumab. Farnesyl
transferase inhibitors include lonafarnib and tipifarnib; HDAC inhibitors
include depsipeptide, vorinostat, and LBH589; PI3K inhibitors include
BEZ235 and XL765; mTOR inhibitors include sirolimus, temsirolimus,
everolimus, and deforolimus; and VEGF receptor inhibitors include
bevacizumab, aflibercept (VEGFtrap), and CT-322. Growth factor ligands
include EGF, PDGF, IGF, TGF, HGF/SF, VEGF, and FGF. Stem-cell
pathways include SHH, wingless family, and Notch. Akt murine
thymoma viral oncogene homologue (also known as protein kinase B),
CDK cyclin-dependent kinase, ERK extracellular signal-regulated kinase,
FGF fibroblast growth factor, FTI farnesyl transferase inhibitors, GDP
guanine diphosphate, Grb 2 growth factor receptor-bound protein 2,GTP
guanine triphosphate, HDAC histone deacetylase, HGF/SF hepatocyte-
growth factor/scatter factor, IGF insulin-like growth factor, MEK
mitogen-activated protein kinase kinase, mTOR mammalian target of
rapamycin, NF1 neurofibromin 1, PIP2 phosphatidylinositol (4,5)
biphosphate, PIP3 phosphatidylinositol 3,4,5-triphosphate, PI3K phos-
phatidylinositol 3-kinase, PKC protein kinase C, PLC phospholipase C,
PTEN phosphatase and tensin homologue, RAF v-raf 1 murine leukemia
viral oncogene homologue 1, RAS rat sarcoma viral oncogene homo-
logue, RTK receptor tyrosine kinase inhibitor, SHH sonic hedgehog, SOS
son of sevenless, Src sarcoma (Schmidt-Ruppin A-2) viral oncogene
homologue, TGF transforming growth factor family, TSC1 and 2 tuberous
sclerosis gene 1 and 2. Reprinted with permission from Wen PY, Kesari S
(2008) Malignant gliomas in adults. N Engl J Med. 359
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